Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry
Authors' conclusion
These results suggest some preferable treatment may exist for improvement of HAQ-DI and pain VAS reduction in the early stage of the treatment, which is a clue to prevention of a criteria of difficult-to-treat RA.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with b/tsDMARDs in the FIRST registry, enrolled August 2013–February 2023, who achieved clinical low disease activities (LDA) (clinical disease activity index (CDAI) ≤ 10.0) at 6 months after starting treatmentachieved LDA at 6 months
- Participants
- 1,424 patients
- Outcome
- Factors associated with HAQ-DI normalization (< 0.5), HAQ-DI improvement (by > 0.22) or pain VAS reduction (≤ 40 mm)
- Follow-up
- 6 months
Methodological detailsmulti-institutional registry (FIRST), multiple logistic regression
- Multi-institutional registry (FIRST)
- Multiple logistic regression
Main finding
As reported in the abstract
Achieved health assessment questionnaire-disability index (HAQ-DI) normalization
732
Achieved pain visual analogue score (VAS) reduction
454
Observational data: associations, not effects.
Original publication
Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry. Arthritis Res Ther. Published 26 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →